[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerotic-plaque\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerotic-plaque":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,93,119,148,171,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585467","phase-4-pcsk9-inhibitor-with-statin-therapy-for-asymptomatic-intracranial-atherosclerosis-100585467",false,"NCT06902740","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial","PISTIAS-2","Inclusion Criteria:\n\n1. Age ≥18 and ≤80, male or female;\n2. Asymptomatic intracranial artery stenosis (50%-99%) in the internal carotid artery (C6-7 segments), middle cerebral artery (M1 segment), vertebral artery (V4 segment), or basilar artery, confirmed by angiography (MRA, CTA, or DSA);\n3. Atherosclerosis identified as the cause of intracranial artery stenosis by high-resolution magnetic resonance imaging;\n4. No previous ischemic cerebrovascular events (including ischemic stroke or transient ischemic attack).\n5. Baseline low-density lipoprotein cholesterol ≥ 1.8 mmol\u002FL;\n6. Informed consent signed.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic intracranial artery stenosis, including arterial dissection; moya moya disease; systemic vasculitis and primary central nervous system vasculitis; varicella-zoster vasculopathy or other viral vasculopathy; neurosyphilis and other intracranial infections, radiation vasculopathy; fibromuscular dysplasia, sickle cell disease, neurofibromatosis; reversible cerebral vasoconstriction syndrome; postpartum vasculopathy; suspected vasospasm, suspected reperfusion after vessel occlusion.\n2. Upstream tandem extracranial vessel stenosis (≥50%) adjacent to the target intracranial stenotic vessel.\n3. Previous treatment of target intracranial lesion with endovascular intervention or plan to perform endovascular intervention within 6 months, including intracranial stenting, endovascular angioplasty, and thrombectomy.\n4. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, extradural, intraventricular) within 90 days prior to enrollment.\n5. Presence of intracranial tumors.\n6. Presence of cerebral aneurysms or arteriovenous malformations with indications for interventional therapy.\n7. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 6 months after enrollment.\n8. Presence of any of the following unequivocal cardiac sources of embolism: mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, chronic or paroxysmal atrial fibrillation.\n9. New York Heart Association (NYHA) class III or IV, or known left ventricular ejection fraction \\\u003C 30%.\n10. Severe liver dysfunction or severe kidney dysfunction: AST and\u002For ALT \\> 3 times the ULN; creatinine clearance \\\u003C 0.6 mL\u002Fs and\u002For serum creatinine \\> 265 μmol\u002FL (\\>3.0 mg\u002FdL); CK \\>5 times the ULN at screening.\n11. Active bleeding diathesis or coagulopathy (e.g., active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \\\u003C 125,000 \u002F uL, hematocrit \\\u003C 30%, Hgb \\\u003C 10 g\u002Fdl, international normalized ratio \\>1.5, bleeding time \\> 1 minute beyond normal value upper limit).\n12. Presence of systemic autoimmune diseases: systemic sclerosis, systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, mixed connective tissue disease, IgG4-related disease.\n13. Dementia or psychiatric problem that hinder their ability to consistently adhere to an outpatient program. Co-morbid conditions that may limit the life expectancy to less than 3 years.\n14. Relative\u002Fabsolute contraindications to magnetic resonance imaging (MRI) (such as presence of internal metallic objects, claustrophobia, contrast agent allergy, severe renal impairment, epilepsy, hypotension, asthma, and other hypersensitivity respiratory diseases).\n15. Uncontrolled hypertension during the screening period, defined as seated systolic blood pressure (SBP) \\> 180 mmHg or diastolic blood pressure (DBP) \\> 110 mmHg.\n16. Prior use of PCSK9 inhibitor before this recruitment.\n17. Known intolerance or allergy to statin.\n18. Pregnancy, lactation, or planning pregnancy.\n19. Currently participating in another study.","ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.",[28,29,30],"Intracranial Atherosclerosis","Intracranial Artery Stenosis","Atherosclerotic Plaque",[28,32,33,34,35,36,37],"intracranial artery stenosis","atherosclerotic plaque","high-resolution magnetic resonance imaging","PCSK9 inhibitor","statin","Recaticimab","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-11-07",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Peking Union Medical College Hospital","OTHER",19,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":75,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years","75 Years",{"count":61,"type":22},140,[63],"NA","INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[66,30,67,68,69,70,71,72,73,74],"Coronary Artery Disease","Coronary Computed Tomography Angiography","Statin Therapy","Multidetector Computed Tomography","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Vascular Diseases","Hyperlipidemia",[76,77,78,79,80,81,33,82],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","statin therapy","2026-05-08",{"date":85,"type":42},"2026-05-13",{"date":87,"type":42},"2025-05-28",{"date":89,"type":22},"2028-12-15",{"name":91,"class":49},"Prof. Maurovich-Horvat Pál",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":19,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":50},"100628792","phase-4-pcsk9-inhibitor-for-intracranial-atherosclerosis-related-acute-ischemic-stroke-100628792","NCT07466251","PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke","PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial","PISTIAS-3","Inclusion Criteria:\n\n* Age \\>=30 and \\\u003C=80;2.Acute ischemic stroke within 72 hours of onset (as determined by CT\u002FMRI in conjunction with neurological deficit symptoms)\n* Acute ischemic stroke within 72 hours of onset (diagnosed by CT\u002FMRI in conjunction with neurological deficit symptoms)\n* NIHSS score of 4-25 at admission\n* Imaging studies (CTA\u002FDSA\u002FMRA) support intracranial atherosclerosis as the cause of stroke, meeting one of the following criteria: i. The culprit vessel exhibits intracranial atherosclerotic stenosis (ICAS) with a narrowing degree of 50-99%; ii. The culprit vessel exhibits intracranial atherosclerotic occlusion (ICAS-LVO), with successful recanalization achieved via mechanical thrombectomy (immediate expanded thrombolysis in cerebral infarction \\[eTICI\\] grade 2b50-3)\n* Informed consent signed\n\nExclusion Criteria:\n\n* Non-atherosclerotic intracranial arterial stenosis (such as arterial dissection, Moyamoya disease, systemic vasculitis, etc.)\n* Any identifiable source of cardiogenic embolism (such as atrial fibrillation, mechanical valves, left ventricular thrombus, patent foramen ovale, etc.)\n* Imaging findings and clinical presentation suggest that the primary pathophysiology of this event is more consistent with cerebral small vessel disease (e.g., perforator artery occlusion\u002Flacunar infarction)\n* Pre-existing disability prior to this ischemic event (modified Rankin Scale ≥ 2 points)\n* CT or MRI findings suggest extensive cerebral infarction (e.g., ASPECTS score \\\u003C 6 or infarct volume ≥ 70 ml)\n* Has undergone or is scheduled to undergo a vascular stent implantation procedure within the next three months\n* Any intracranial hemorrhage occurring within 3 months prior to enrollment;\n* Intracranial tumors, cerebral aneurysms, or arteriovenous malformations that are assessed as having indications for interventional treatment\n* Severe active bleeding tendency or coagulation disorder\n* Severe dysfunction of vital organs such as the heart, liver, and kidneys\n* Received PCSK9 monoclonal antibody inhibitor therapy within 1 month prior to enrollment or PCSK9 siRNA inhibitor therapy within 6 months prior to enrollment\n* A clear contraindication to statins or a history of intolerance to them\n* Pregnancy, breastfeeding, or planning pregnancy;14.Currently participating in another study","30 Years",{"count":103,"type":22},1212,[25],"This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.",[107,108,30],"Acute Ischemic Stroke AIS","Intracranial Atherosclerosis ICAS",[28,32,33,35,37],"NOT_YET_RECRUITING","2026-03-11",{"date":113,"type":42},"2026-03-12",{"date":115,"type":22},"2026-09-01",{"date":117,"type":22},"2029-12-31",{"name":48,"class":49},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":126,"minAge":127,"maxAge":58,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100548735","phase-1-fish-oil-metformin-and-heart-health-in-pcos-100548735","NCT06424860","Fish Oil, Metformin and Heart Health in PCOS","Dietary Fish Oil and Metformin Intervention for Heart Health in PCOS","Inclusion Criteria:\n\n* diagnosis of PCOS\n* overweight-obese (BMI \\>25 kg\u002Fm2)\n* elevated fasting plasma TG (\\>150 mg\u002FdL)\n* and\u002For apoB48-remnant cholesterol lipoproteins (\\>20 ug\u002Fml)\n* impaired insulin sensitivity (glucose 100-125 mg\u002FdL and\u002For insulin \\>15 (uM\u002Fml), and may be diagnosed with T2D (blood glucose \\>126 mg\u002FdL).\n\nExclusion Criteria:\n\n-pregnancy, lactation","FEMALE","25 Years",{"count":129,"type":22},146,[131],"PHASE1","Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.",[134,135,136,30,137],"PCOS","Cardiovascular Disease","Atherosclerotic Cardiovascular Disease","Cardiac Hypertrophy","2025-12-04",{"date":140,"type":42},"2025-12-12",{"date":142,"type":42},"2025-11-01",{"date":144,"type":22},"2027-12-30",{"name":146,"class":49},"University of Alberta",3,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":92},"100502410","carotid-plaque-imaging-project-cpip-100502410","NCT05821894","Carotid Plaque Imaging Project (CPIP)","Carotid Plaque Imaging Project (Identification of Vulnerable Atherosclerotic Plaques With Imaging and Biological Markers)","CPIP","Inclusion Criteria:\n\n* Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old that cannot provide informed consent; pregnant.",{"count":157,"type":22},3500,"OBSERVATIONAL","The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.",[161,30],"Atherosclerosis","2024-10-09",{"date":164,"type":42},"2024-10-15",{"date":166,"type":42},"2005-10-26",{"date":168,"type":22},"2029-12",{"name":170,"class":49},"Lund University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":92},"100472917","stabilization-of-atheroma-by-lipid-reducing-effect-of-drug-coated-balloon-stable-dcb-100472917","NCT05438121","STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)","Drug-Coated Balloon Angioplasty Facilitates Rapid Reduction in Plaque Lipid Burden in Patients with Multivessel Coronary Artery Disease: a Serial NIRS-IVUS Imaging Study","STABLE-DCB","Inclusion Criteria:\n\n* Patients with significant multivessel coronary artery disease requiring revascularization\n* Any De novo lesions (reference vessel diameter of 2.25mm\\~4.0mm) suitable for DCB angioplasty\n* Lesion suitable for intravascular imagings\n* Written informed consent\n\nExclusion Criteria:\n\n* Hemodynamically unstable or cardiogenic shock\n* Left main stenotic lesion or graft vessel lesion\n* Visible angiographic thrombus, not resolved by balloon angioplasty\n* Pregnancy or breastfeeding\n* Comorbidities with life expectancy \\\u003C 12 months\n* Severe coronary calcification or tortuosity, hindering timely DCB delivery","85 Years",{"count":181,"type":22},65,"This study aims to investigate whether DCB angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.",[66,30,184],"De Novo Stenosis",[186,187,188,189],"drug coated balloon","Near infrared spectroscopy","NIRS-IVUS","De novo coronary lesion",{"date":164,"type":42},{"date":192,"type":42},"2022-10-13",{"date":194,"type":22},"2026-12-31",{"name":196,"class":49},"Korea University Ansan Hospital",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":205,"sex":17,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":92},"100451302","pakistan-study-of-premature-coronary-atherosclerosis-in-young-adults-100451302","NCT05156736","Pakistan Study of Premature Coronary Atherosclerosis in Young Adults","Pakistan Study of Premature Coronary Atherosclerosis in Young Adults (PAK SEHAT)","PAKSEHAT","Inclusion Criteria:\n\n* Native Pakistani\n* Men aged 35-60 years \\& women aged 35-65 years\n* Willing to consent to participation\n\nExclusion Criteria:\n\neGFR \\\u003C 60 ml\u002Fmin\u002F1.73m2\n\nPregnant women\n\nHistory of stroke or MI (CABG or PCI)\n\nHistory of Peripheral arterial disease\n\nWeight more than 102 Kg\n\nAny active malignancy\n\nKnown contraindication from contrast used in cardiac CTA\n\nExpected migration from residential area within 5 years",true,"35 Years","65 Years",{"count":209,"type":22},2000,"Coronary heart disease (CHD) is a major cause of morbidity, disability, mortality, and health expenditures worldwide. A wealth of studies has demonstrated that people of South Asian ancestry have a higher risk of CHD and particularly premature CHD than most other racial\u002Fethnic groups, and recent research suggests that this risk is higher in Pakistanis than in Indians-the two largest SA groups. Pakistan is the 5th most populous country in the world, and despite these concerning trends, so far there has been a scarcity of large studies evaluating the prevalence of cardiovascular risk factors and subclinical coronary atherosclerosis in young-to-middle-aged Pakistanis. Also, there is currently no cardiovascular risk score specifically tailored to younger Pakistani men and women. The PAKistan Study of prEmature coronary atHerosclerosis in young AdulTs (PAK-SEHAT) aims at addressing these important gaps. PAK-SEHAT is an ongoing prospective cohort study that will enroll 2,000 asymptomatic Pakistani men aged 35 to 60 years and women aged 35 to 65 years from the general population, free of clinically overt cardiovascular disease. Participants will undergo a comprehensive baseline exam including coronary computed tomography angiography, and will be followed for incident events and repeat testing for 5 years. PAK-SEHAT will allow determining the prevalence, severity, determinants, and prognostic significance of early atherosclerosis in apparently healthy young-to-middle-aged Pakistanis. This knowledge can help inform primordial and primary prevention strategies, enhanced cardiovascular risk stratification, and potential plaque-screening approaches in Pakistan, all of which can ultimately help reduce the burden of CHD in the country. In this report investigators describe the rationale, objectives, methods, and discuss the potential implications of the PAK-SEHAT study.",[30,212,213,214],"Diabetes Mellitus, Type 2","Hypertension","Stroke",[216,217,218,219,220,221],"ATHEROSCLEROSIS","CARDIOVASCULAR DISEASE","SOUTH ASIAN","YOUNG","PAKISTAN","EPIDEMIOLOGY","2023-04-05",{"date":224,"type":42},"2023-04-07",{"date":226,"type":42},"2023-03-15",{"date":228,"type":22},"2028-11",{"name":230,"class":49},"Tabba Heart Institute"]